Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Therapeutic-dose anticoagulation with heparin - XML Representation

Raw xml | Download

<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="7751"/>
  <meta>
    <versionId value="13"/>
    <lastUpdated value="2024-11-19T17:01:54.513Z"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
  </text>
  <url value="https://fevir.net/resources/EvidenceVariable/7751"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/7751"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.4.642.40.44.24.55"/>
  </identifier>
  <version value="2.0.0-ballot"/>
  <name value="Therapeutic_dose_anticoagulation_with_heparin"/>
  <title value="Therapeutic-dose anticoagulation with heparin"/>
  <status value="active"/>
  <date value="2022-08-05T14:37:53.832Z"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Brian S. Alper"/>
  </author>
  <relatedArtifact>
    <type value="cite-as"/>
    <citation
              value="Therapeutic-dose anticoagulation with heparin [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7751. Revised 2022-08-05. Available at: https://fevir.net/resources/EvidenceVariable/7751. Computable resource at: https://fevir.net/resources/EvidenceVariable/7751."/>
  </relatedArtifact>
</EvidenceVariable>